[1H-pyrazolo[3, 4-d]pyrimidin-4-yl]- piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases

Details for Australian Patent Application No. 2005322085 (hide)

International Classifications

Event Publications

12 July 2007 PCT application entered the National Phase

PCT publication WO2006/071819 Priority application(s): WO2006/071819

29 November 2007 Amendment Made

The nature of the amendment is: Amend the invention title to read [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases

3 January 2008 Corrigenda

Amendments, Section 104 - Amendments Made Under the name Exelixis, Inc., Application No. 2005322085, under INID (54), correct the invention title to read [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases

19 July 2012 Application Accepted

Published as AU-B-2005322085

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.